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Executive Summary
Nigeria is committed to achieving a modern contraceptive prevalence rate of  27 percent by 2020; yet current 
estimates show only 11 percent of  women age 15-49 years old use modern contraceptive methods. Among 
both public and private family planning (FP) service providers, Patent and Proprietary Medicine Vendors 
(PPMV) are the most popular source for voluntary contraceptive services. According to Nigeria’s 2013 National 
Demographic Health Survey, 38 percent of  all contraceptive users and 13 percent of  injectable users received 
their method from a PPMV.
The Evidence Project, led by the Population Council with support from the U.S. Agency for International 
Development, collaborated with the Federal Ministry of  Health (FMoH), state ministries of  health, and pro-
fessional associations to conduct an implementation science study in Bauchi, Cross River, Ebonyi, Kaduna, 
Nasarawa and Oyo States representing each of  Nigeria’s six geo-political zones. The study objectives were to: 
• Assess the feasibility of  PPMVs in the provision, specifically the administration, of  voluntary injectable 
contraceptives1; and
• Explore injectable contraceptive users’ experiences and quality of  care received when accessing contra-
ceptive services from PPMVs.
PPMVs received a 1-week training on FP counseling, sale, referral and administration of  all progestin-only 
injectable contraceptives. Trainings in Nasarawa and Oyo were held in November 2015, and in Bauchi, Cross 
River, Ebonyi and Kaduna in May and June of  2017. Learnings from Nasarawa and Oyo were applied to 
the implementation process in Bauchi, Cross River, Ebonyi and Kaduna, including an observation checklist 
that was added to the monitoring visits one and six months after the training. Monitoring teams comprised 
of  national, state and local-level ministry officials, National Association of  Patent and Proprietary Medicine 
Dealers (NAPPMED) and Pharmacy Council of  Nigeria (PCN) representatives visited PPMVs two-to-three 
times over nine months.
Trained data collectors conducted face-to-face interviews with PPMVs before, after, and nine months following 
the training. Injectable contraceptive clients were interviewed within five days after receiving an injection from 
a trained PPMV and were followed over nine months by phone. Written informed consent was obtained from 
all respondents participating in the study. The research protocol received ethical approval from the Population 
Council’s Institutional Review Board, National Health Research Ethic Committee, the Ethical Committee at 
University of  Ibadan and ethics committees based at state ministries of  health in Bauchi, Cross River, Ebonyi 
and Kaduna. 
Almost all PPMVs were providing some form of  injectable contraceptive services (counseling, sale, referral or 
administration) and 49 percent had administered an injectable in their shop before the training. Forty percent 
of  clients had visited a study-enrolled PPMV for injectable services before the trainings. Key study findings are 
summarized below:
PPMVs can administer injectable contraceptives safely
• PPMVs demonstrated competency in nine key steps for safe administration of  intramuscular depot 
1 DMPA-IM (Depo-Provera), NET-EN (Noristerat) and DMPA-SC (Sayana Press)
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medroxyprogesterone acetate (DMPA-IM) and nine key steps for safe administration of  subcutaneous 
DMPA (DMPA-SC) using models immediately and six months after the training in front of  a Master 
Trainer in Bauchi, Cross River, Ebonyi and Kaduna.
• Nearly all PPMVs (98%) were observed having a sharps disposal box in use in their shop by the moni-
toring teams in Bauchi, Cross River, Ebonyi and Kaduna.
There was no difference in knowledge and skills between PPMVs with and without previous health 
facility experience 
• PPMVs without prior health facility experience had similar or higher levels of  knowledge to those with 
health facility experience on:
 – 44 of  the 50 injectable contraceptive characteristics at the post-training survey
 – 46 of  the 50 injectable contraceptive characteristics at the 9-month follow-up survey
• PPMVs with no health facility experience demonstrated similar levels of  competency in almost all 
the steps required for safe administration of  DMPA-IM and DMPA-SC to those with health facility 
experience.
PPMVs’ knowledge of injectable contraceptive characteristics was higher after the training and 
PPMVs retained this knowledge nine months later 
• PPMVs had significantly higher knowledge on 47 of  50 injectable contraceptive indicators2 post-training.
• PPMV retained or improved knowledge for 42 of  the 50 indicators at the 9-month follow-up survey. 
Knowledge specifically increased for 13 of  those 42 indicators.
• Despite overall knowledge gains across most indicators, knowledge on some indicators like side effects 
and exclusionary health conditions remained low at the 9-month follow-up survey. Non-prompted 
questions were used to assess PPMVs knowledge. These questions may not accurately reflect PPMVs 
knowledge as clients reported receiving key information from PPMVs, specifically side effects, and 
86% of  PPMVs reported using either the MEC wheel, BCS cards and or DMPA screen checklist, when 
counseling their clients. 
Clients reported receiving quality FP counseling and were satisfied with injectable services 
received from PPMVs
• Over 80 percent of  clients reported receiving information on 9 quality of  care indicators3 at their first 
injection visit from a trained PPMV. At their second and third injection visits, most clients continued to 
report quality counseling. 
• Over 97 percent of  clients reported that they would return to the PPMV for their next injection and 100 
percent would recommend that PPMV to a friend for injectable contraceptive services.
2 The 50 indicators are described in the Results section starting on page 20 and include: side effects (7), exclusionary health conditions (11), 
when a woman can start the injectable (6), instructions for clients after the injection (6), method-specific characteristics (9), how to handle 
needles safely (5), how to avoid infection from needlestick injury (3), and what to do if  there is a needlestick injury (3)
3 The 9 quality of  care indicators include: (1) being asked the reason for your visit; (2) told about other FP methods; (3) asked about previous 
use of  the injectable (4) asked about reasons for choosing the injectable (5) told when to return for the next injection (6) told what to do if  
you experiences a problem with the injectable; (7) told about potential side effects (8) told about potential actions to resolve problems with 
the side effect; and (9) reported feeling comfortable asking questions.
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Clients who discontinued the injectable contraceptive did so for reasons unrelated to PPMV 
service quality 
• Of  the 22 percent of  clients (66/294) in Bauchi, Cross River, Ebonyi and Kaduna who reported discon-
tinuing the injectable contraceptive method or stopping injectable services from PPMVs, the top three rea-
sons were: didn’t have time to go back (21%); wanted to become pregnant (20%), and side effects (18%). 
Clients reported a variety of  reasons for seeking injectable contraceptive services from PPMVs. Many do so 
because it is more convenient. Policy change that would allow PPMVs to offer injectable administration could 
improve access to FP counseling and injectable contraceptives for more women throughout Nigeria. If  policy 
were to be changed, the following considerations could assist in scale-up:
• The curriculum used in this study was based on existing, validated materials. Most PPMVs strongly 
agreed that the curriculum used in this study improved their knowledge and skills to provide FP coun-
seling and voluntary injectable contraceptive services. Using existing materials can help save time when 
training PPMVs in injectable contraceptive service provision.
• Job aids that are designed to help providers adhere to counseling and screening guidelines are acceptable 
to PPMVs. Most PPMVs used the job aids that were provided in the study; job aids can help alleviate 
the burden of  memorizing long lists of  information. 
• Better linkages between the PPMVs and the public sector are needed to ensure effective referrals for any 
contraceptive method and proper disposal of  sharps. 
• PPMVs require monitoring support by the state and local governments. Additional support would be 
needed to ensure PPMVs do not experience harassment from law officials. This potential for harassment 
can prohibit PPMVs from keeping up-to-date records of  FP counseling, and sale and administration of  
injectable contraceptives.
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Introduction
With a population of  approximately 214 million people, Nigeria is Africa’s most populous nation (Population 
Reference Bureau, 2018). Modern contraceptive methods remain underutilized in Nigeria (only 11% of  married 
women of  reproductive age use modern contraceptives) [MICS, 2017] despite efforts to expand access to FP 
over the past two decades. Approximately 40 percent of  modern contraceptive users use an injectable contra-
ceptive, 21 percent use oral contraceptives, 13 percent use an implant, 10 percent use male condoms and 16 
percent use various other methods (MICS, 2017). Among both public and private sources, PPMVs are the most 
popular source for modern contraceptives (NPC and ICF, 2014) for many reasons including (a) widespread 
availability throughout Nigeria, (b) consistent drug stocks, (c) extended operational hours including weekends, 
(d) personable interactions, and (e) no separate fees for consultations (Brugha 2002; Adetunji 1991). Nigerian 
pharmacy laws prohibit PPMVs from selling and administering injectable contraceptives due to a lack of  formal 
training in injectable contraceptive services (NPC, 2008 & 2003). Even with this restriction, 13 percent of  
injectable contraceptive users received an injectable contraceptive from a PPMV (NPC and ICF, 2014). 
The FMoH recognizes the important role that PPMVs can play in the delivery of  modern contraceptive ser-
vices and recommends that PPMVs should motivate, counsel, and refer clients for contraceptive services, 
supply non-prescription contraceptives, and resupply oral contraceptive pills (FMoH, 2009). Although several 
studies have explored the role of  PPMVs in offering contraceptive services broadly (Oye-Adeniran et al, 2006; 
Ajayi, 2009), few have specifically assessed the contribution of  PPMVs in delivering injectable contracep-
tives, the implementation considerations, and their clients’ experiences receiving these services (Ajuwon et al. 
2013). For these reasons, the Evidence Project, led by the Population Council and funded by the United States 
Agency for International Development (USAID), collaborated with the FMoH and state ministries of  health 
to conduct an implementation science study to assess the feasibility and acceptability of  PPMVs’ provision of  
injectable contraceptive services. 
This report summarizes the results of  the implementation science study and identifies programmatic implica-
tions for PPMVs to safely deliver injectable contraceptive services, including the mentorship and support that 
would be needed if  PPMVs were legally allowed to administer injectable contraceptives. Results from this study 
will contribute to task shifting4 policy in Nigeria with the potential to improve women’s access to contraceptive 
services offered by PPMVs.
4 Task shifting is the shifting of  specific tasks or services that have traditionally been done by specialized health workers to those with less 
training (WHO, 2007)
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Objectives
The goal of  this study was to improve access of  voluntary family planning services for women and couples in 
Nigeria. The study objectives were to:
• Assess the feasibility of  PPMVs in the provision, specifically the administration of  DMPA-IM (Depo-
Provera), NET-EN (Noristerat), and DMPA-SC (Sayana Press); and
• Explore the experiences of  injectable contraceptive users and the quality of  care they receive when 
accessing injectable contraceptive services from PPMVs.
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Methods
Study design
The study was implemented in Bauchi, Cross River, Ebonyi, Kaduna, Nasarawa and Oyo states. PPMVs enrolled 
in the study participated in a five-day training covering FP counseling and the provision of  progestin-only 
injectable contraceptive services (including counseling, sale, referral and administration), and were routinely 
monitored after the training. USAID Washington funded implementation in Nasarawa and Oyo states. The 
USAID Mission in Nigeria provided additional funding to expand the study to Bauchi, Cross River, Ebonyi, 
and Kaduna so that the overall study included one state from each geo-political zone. Ministry officials, Master 
Trainers, non-governmental organizations (NGOs), professional associations, and the Population Council 
modified the intervention and the study design for Bauchi, Cross River, Ebonyi and Kaduna by reviewing 
results and implementation experiences from Oyo and Nasarawa. The modifications included (a) adjusting the 
PPMV data collection and monitoring time points, (b) adding questions to the PPMV and client survey tools, 
(c) updating the training curriculum, and (d) providing PPMVs with job aids.
The overall study design remained the same despite these modifications. In all six states, the Evidence Project 
collected data from PPMVs and their injectable contraceptive clients over a 9-month period. 
Study population and recruitment
The study took place in six of  the 36 states in Nigeria: Bauchi, Cross River, Ebonyi, Kaduna, Nasarawa and 
Oyo. The states were selected in collaboration with the FMoH and the USAID Mission in Nigeria to represent 
each of  the six geopolitical zones of  Nigeria. In each state, four Local Government Areas (LGAs), (two urban 
and two rural) were randomly selected by simple balloting for a total of  twenty-four. The categorization of  
rural or urban LGAs was obtained from state government websites. The number and selection of  LGAs were 
determined in collaboration with the respective states’ ministries of  health.
Patent and proprietary medicine vendors
PPMVs are frontline service providers who operate in Nigeria’s informal health sector. In Nigeria, a PPMV is 
defined by the Pharmacy Law as someone who is licensed by the State Ministry of  Health to sell pre-packaged, 
over the counter medications (FMoH, 1946). The Pharmacy Law requires that applicants be at least 21 years 
old and submit the names of  two references to obtain a license. By custom, PPMVs are expected to have com-
pleted a minimum of  primary school education (Liu, 2014). Most PPMVs learned to sell and dispense medicine 
through apprenticeships with licensed PPMVs.
In Nasarawa and Oyo, announcements were made during NAPPMED meetings in each of  the study LGAs. 
NAPPMED is the main professional association of  PPMVs in Nigeria. The announcement included the study’s 
goal and methodology, and the training PPMVs would receive if  enrolled. The local NAPPMED chapter nom-
inated PPMV members using three criteria: 
1. Interested and willing to participate
2. Able to read and write in English, and speak English and either Yoruba or Hausa
3. Committed to attend all training sessions
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NAPPMED sent a shortlist of  candidates to the research team. PPMVs were randomly selected from that list 
to participate in the study. Selected PPMVs were sent formal invitations with information on the dates and 
location for the training. 
In Bauchi, Cross River, Ebonyi and Kaduna, PPMVs were primarily recruited in collaboration with PCN, which 
is the regulatory body for PPMVs in Nigeria. PCN was more actively engaged in the additional four states due 
to its key role in overseeing PPMV services. Each PCN state officer nominated PPMVs based on the following 
criteria:
• Licensed with PCN
• Interested and willing to participate
• Able to read and write in English
• Committed to attend all training sessions
NAPPMED assisted with PPMV recruitment in LGAs where PPMV licensure with PCN was low. As in 
Nasarawa and Oyo, PPMVs were randomly selected from the shortlist of  candidates identified by PCN. Selected 
candidates were contacted and invited to trainings at the state level. PPMVs were retained in the study if  they 
demonstrated competence in administering DMPA-IM and DMPA-SC injections on dummy models. A Master 
Trainer used an observation checklist to evaluate PPMV skills. 
Injectable contraceptive clients
For a 3-month period after the training, participating PPMVs referred eligible clients to be interviewed for the 
study. The referral period was extended to four months in Bauchi, Cross River, Ebonyi and Kaduna to reach 
the desired sample size. Eligible clients were those who were administered a progestin-only injectable contra-
ceptive from a trained PPMV. PPMVs informed clients about the study and requested permission to share the 
client’s name and phone number with the study team for follow-up. If  a client agreed to participate, a trained 
data collector called the client within five days of  her visit to the PPMV. At the time of  the telephone interview, 
the interviewer asked a set of  questions to ensure that the respondent was aware of  the study and then read the 
informed consent statement (see section on Ethical Considerations) before proceeding with the questionnaire. 
Any client who came to a PPMV outside of  the 3- to 4-month referral window was not enrolled in the study.
Data collection
Data collectors training
Four data collectors and one supervisor were recruited in each state to conduct PPMV and client interviews. 
Data collectors and supervisors were trained in four-day data collection training. Content included:
• an overview of  the study and its goals
• a description of  PPMVs and their role in the health care system
• a discussion of  the importance of  research ethics, including privacy and confidentiality
• the PPMVs’ role in ensuring confidentiality, privacy, and anonymity
• informed consent and the consent forms
• thorough review of  interview questions and their purpose
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• the data collection timeline
• data management
The training combined traditional lecture with adult learning methodologies including role play and mock inter-
views with clients and PPMVs. Mock interviews were conducted with non-participating PPMVs identified by 
the local NAPPMED chapter, and volunteers acted as mock clients. The supervisors received additional infor-
mation on (a) their role as a supervisor, (b) the data management process, (c) how to identify data collection 
issues, and (d) to how to seek guidance from the research team to resolve issues.
Data collection 
Nasarawa and Oyo
Data collection for the PPMVs began in November 2015. Data collected from PPMVs included (a) a pre-test 
survey and (b) 1-, 3-and 9-month follow-up surveys. The pretest survey was administered before the training 
and included demographic questions and knowledge questions on injectable contraceptives (e.g. frequency and 
administration location, counseling on side effects and method effectiveness, eligibility criteria, supplies, and 
proper storage and disposal of  drugs). Follow-up surveys were conducted in person at the PPMV’s shop one, 
three and nine months after the training. The follow-up surveys were identical at each time point and included 
questions on the type of  injectable services provided, and the knowledge questions in the pretest survey. 
Initial telephone interviews with clients were conducted between December 2015 and February 2016. The first 
interview included questions on (a) client demographics, (b) previous FP and injectable use, (c) type of  services 
received, (d) experience and satisfaction with PPMV services, and e) satisfaction with the injectable method. 
The same survey, minus the demographic questions, was administered after the respondents’ expected second 
and third injection. A 2-week window after the expected injection date was used to interview clients for the fol-
low-up surveys. Clients who were no longer using the injectable or did not receive the injectable from a trained 
PPMV were not interviewed but were contacted again at the time of  the next follow-up interview. 
Bauchi, Cross River, Ebonyi and Kaduna
Data collection for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna began in May 2017. Minor modifica-
tions were made to data collection process based on the experience in Nasarawa and Oyo. A post-test training 
survey was included to compare knowledge immediately before and after the training. The follow-up surveys 
were conducted only three and nine months after the training to avoid duplication with the monitoring visits 
(see section on Monitoring and Supervision).
The pretest and follow-up surveys were almost identical to those used in Oyo and Nasarawa, but included addi-
tional questions related to PPMV knowledge of  NET-EN and their stock of  other FP methods. Data collectors 
administered the post-test on the last day of  the training. The post-test included the same set of  questions as 
the pretest survey, excluding the demographic and store practice questions. 
Follow-up surveys were conducted in person at the PPMV’s shop three and nine months after the training. The 
surveys included questions on the type of  injectable services provided since the training and the knowledge 
questions from the pre-test survey.
Initial telephone interviews with clients were conducted between May 2017 and September 2017. The first 
interview and follow-up surveys were similar to those used in Nasarawa and Oyo except the follow-up surveys 
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included a subset of  questions for clients who stopped using the injectable or stopped receiving injectable ser-
vices from PPMVs. Several questions on quality were also added to the client surveys. Based on the experience 
in Nasarawa and Oyo, the interview window for follow-up surveys was extended from two to four weeks after 
scheduled injection date.
Data management and analysis
Data management
Data collection supervisors checked survey data for completeness and accuracy. Completed questionnaires 
were sent to the Population Council office in Abuja for review by the Program Officer. All completed surveys 
were stored in locked files at the Population Council office and access to the surveys was strictly limited to the 
research team. Only the Program Officer had access to respondent names, study identification numbers, and 
the instruments. Completed questionnaires were entered into Statistical Package for Social Sciences (SPSS) 
software and analyzed using Stata 14 software. 
Data analysis
Descriptive statistics and bivariate analyses were conducted. Chi-square tests were used to determine significant 
associations over time and between PPMVs with and without previous health facility experience. T-tests were 
used to determine significance differences in the mean knowledge scores between the initial phase (Nasarawa 
and Oyo) and the expanded phase (Bauchi, Cross River, Ebonyi and Kaduna).
Ethical considerations
Ethical review
The research protocol, including the data collection tools and informed consent forms, received ethical approval 
from the Population Council’s Institutional Review Board, and the Ethical Committee, College of  Medicine at 
the University of  Ibadan. Ethical approval was also received in each state. The FMoH approved the study. All 
data collection activities involving human subjects began only after full approvals were received from relevant 
ethical review boards. 
Informed consent 
Structured, written informed consent forms were used during in-person interviews with PPMVs and over the 
phone with clients. The consent form provided respondents with (a) information on the study objectives, (b) 
methodology, (c) measures to protect their privacy, confidentiality and anonymity, and (d) who to contact for 
additional information or if  there was a problem. Before the start of  each survey, a trained data collector read 
the informed consent form and explained its contents. PPMVs were given a copy to read and keep. A data 
collector asked each PPMV for his/her written consent and clients for their verbal consent over the phone. 
Informed consent was received by all respondents at the start of  each survey.
Confidentiality
Each respondent received a unique identification (ID) number during the first interview. This unique ID code 
was recorded on the questionnaires and no other personal identifying information was recorded on the ques-
tionnaires. Documents containing names of  participants, including the informed consent forms, were kept phys-
ically separate from the questionnaires in a locked cabinet at the Population Council office in Abuja, Nigeria. 
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Description of the Intervention
Stakeholder engagement
The Evidence Project collaborated with stakeholders throughout the life of  the study including in the design, 
implementation, and results interpretation phases. For example, the original protocol only included training 
PPMVs to counsel, sell and refer clients for injectable services. To ensure the study’s results would provide pol-
icymakers and program implementers with the evidence needed, the Population Council in coordination with 
the FMoH presented the original protocol to the National Reproductive Health Technical Working Group. At 
this meeting, Technical Working Group members highlighted the need for evidence on PPMV administration 
of  injectable contraceptives. As a result, the protocol and intervention were expanded to include administra-
tion. Stakeholder engagement continued in the monitoring visits where national, state and local-level ministry 
officials were members of  the monitoring team (see section on Monitoring and Supervision). 
The Evidence Project, federal, state and local ministries of  health, NGOs and professional associations reviewed 
the training curriculum used in Nasarawa and Oyo alongside results from these two states. The curriculum was 
revised to improve outcomes for certain topics. Examples of  revisions made to the curriculum and training 
include: 
• reduce lecture time and increase hands-on practice and small group activities
• provide a clearer definition of  common side effects versus adverse events
• simplify language used in the screening checklist for injectable users
The revised curriculum was used in Bauchi, Cross River, Ebonyi and Kaduna. PPMVs in these states were 
asked a series of  question at the 9-month survey to understand their perceptions of  the training (n=194). One 
hundred percent agreed with the following two statements, 1) “the training improved my knowledge and skills 
to provide injectable contraceptives” and 2) “the training improved my knowledge and skills in FP counseling” 
(data not shown). When asked how easy or difficult they found the training, 72 percent said the training was 
easy to very easy and 26 percent said it was moderate. Only 2 percent of  PPMVs found the training to be dif-
ficult or very difficult. 
Overall, knowledge outcomes were not higher in the additional four states compared to knowledge outcomes 
in Oyo and Nasarawa. Knowledge of  injectable contraceptive side effects, however, was higher in Bauchi, Cross 
River, Ebonyi and Kaduna. The mean number of  side effects named by PPMVs in Nasarawa and Oyo was 3.2 
compared to 3.8 in the additional four states at the 9-month survey (p-value 0.01). In addition, fewer PPMVs in 
Bauchi, Cross River, Ebonyi and Kaduna incorrectly reported side effects as adverse and severe adverse events 
during the follow-up surveys and monitoring visits. For example, PPMVs in Nasarawa and Oyo frequently 
reported common side effects (e.g. irregular bleeding, weight gain, spotting) as adverse events. This revealed 
that many PPMVs confused normal side effects with the adverse events that should be reported. In Phase II, 
only two PPMVs incorrectly reported side effects as adverse event. 
PPMV training
Trainings were held in November 2015 in Nasarawa and Oyo, and in May and June 2017 in Bauchi, Cross River, 
Ebonyi and Kaduna. PPMVs were trained to provide FP counseling and progestin-only injectable contracep-
tive services (counsel, sell, refer and administer). Master Trainers who were certified to lead FP trainings in 
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Nigeria facilitated the trainings. The curriculum was based on a set of  training materials developed by PATH 
on DMPA-SC5 and FHI 360 on DMPA injections for public providers.6 The training included adult learning 
methodologies such as role play, group discussion, and hands-on practice. PPMVs were trained to counsel and 
screen clients using the World Health Organization’s Medical Eligibility Criteria (MEC) Wheel, the Population 
Council’s Balanced Counseling Strategy Plus (BCS+) and FHI 360’s Checklist for Screening Clients Who Want 
to Initiate DMPA (or NET-EN). 
Based on learnings from Nasarawa and Oyo, PPMVs were given job aids at the end of  the trainings in Bauchi, 
Cross River, Ebonyi and Kaduna to ensure they could properly screen and counsel clients. Each PPMV was 
given a WHO MEC wheel, a copy of  the BCS+ cards, and the FHI 360 DMPA screening checklist. During 
the stakeholders meeting to review the curriculum, the FHI 360 DMPA screening checklist was simplified to 
ensure that PPMVs with all levels of  education could correctly screen clients interested in using the injectable. 
PPMVs in the Bauchi, Cross River, Ebonyi, and Kaduna were given job aids during the training and were asked 
about their use of  job aids during the 9-month survey. The majority of  PPMVs (86%) reported using the job 
aids with some to all of  their clients when providing FP services (data not shown). Among those who reported 
using job aids with their clients (n=168), 78 percent reported using the WHO MEC Wheel, 70 percent reported 
using BCS+, and 46 percent reported using the FHI 360 screening checklist. 
Monitoring and supervision
A monitoring team comprised of  the research staff, a Master Trainer, and key stakeholders visited PPMVs in 
their shops after the training. The purpose of  the monitoring visits was to: (1) observe the quality of  injectable 
services offered by PPMVs, especially drug storage and disposal of  sharps; (2) provide support and mentorship 
to PPMVs; and (3) provide stakeholders an opportunity to see the study’s progress, discuss implementation 
challenges and solutions with PPMVs, and see what would be needed to broaden this program in their state. 
The monitoring team used a form that included questions on the implementation challenges faced by PPMVs 
and questions similar to those on knowledge and service provision in the follow-up survey. 
In Nasarawa and Oyo, each PPMV was visited one, three and nine months after the training. The monitoring 
team consisted of  members from the research team, a Master Trainer, and federal, state and local ministry of  
health staff, and a NAPPMED representative. Based on the monitoring team’s observations, and overall results 
from Nasarawa and Oyo, some changes were made to the monitoring visits conducted in Bauchi, Cross River, 
Ebonyi and Kaduna. First, a PCN representative in the project state was included in the monitoring team. 
This was to ensure that PCN as the regulatory body for PPMVs, could observe PPMVs progress and provide 
guidance on implementation challenges. Second, PPMVs were monitored one and six months after the training. 
This reduced the total number of  monitoring visits from three to two to avoid duplication with other data col-
lection activities. Third, PPMVs were asked to role play administering DMPA-IM and DMPA-SC in front of  
the Master Trainer. The Master Trainer assessed PPMVs’ skills using the observation checklist used at the post-
test. Fourth, the monitors answered questions related to their observations of  the PPMV’s shop to understand 
whether PPMVs were properly storing and disposing sharps and keeping records of  injectable clients.
5 https://www.path.org/resources/dmpa-sc-training-materials/
6 https://www.fhi360.org/sites/default/files/media/documents/checklist-dmpa-english.pdf
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Results
A total of  388 PPMVs participated in the five-day training. Seven PPMVs were dropped after the training 
because they either did not demonstrate competence in injectable administration by the end of  the training 
or did not participate in all the sessions. This brought the total sample size to 381. In Nasarawa and Oyo, 
four PPMVs were unavailable for the post-test survey, which took place one month after the training.7 By the 
9-month survey, 38 PPMVs were either dropped from the study or were unavailable at the time of  data col-
lection. This brought the total sample for the 
9-month survey to 343. Analyses were con-
ducted cross-sectionally and included data 
from all PPMVs interviewed at each respec-
tive survey time-point.
PPMV characteristics and 
family planning services 
provided before the training
Table 1 shows the characteristics of  PPMVs 
enrolled in the study at the pretest survey. 
Enrolled PPMVs were a diverse group of  ser-
vice providers. The majority (72%) were male, 
67 percent were between 30 and 49 years of  
age, and 92 percent had at least a secondary 
education. Twenty-eight percent had previ-
ously worked in a health facility and only 21 
percent had been working as a PPMV for less 
than five years. Two-thirds of  PPMVs (74%) 
reported that their shops were open seven 
days a week.
At the pretest survey, PPMVs were asked the 
FP methods that they knew, the types of  FP 
methods they sold, and types of  injectable 
contraceptive services that they provide. Table 
2 shows PPMVs’ unprompted responses to 
FP knowledge. The majority of  PPMVs knew 
about the male condom (93%), the pill (90%), 
and the injectable (86%). Only 28 percent 
knew of  emergency contraceptives and less 
than a quarter could name the IUD (23%) the 
implant (24%), or the vaginal ring (24%). Fewer 
7 In Nasarawa and Oyo, the post-test survey was con-
ducted one month after the training. For the purposes 
of  the analysis, these data were combined with post-test 
data from Bauchi, Cross River, Ebonyi and Kaduna.







17 - 29 19.7
30 - 39 41.7
40 - 49 25.5
50+ 13.1
Highest level of education
Primary school 8.4
Secondary school (WASC/GCE) 44.4
Two years of post-secondary (OND/NCE) 25.7
College degree (HND/1st degree) 16.3
Post graduate degree/other 5.2
Years working as a PPMV
Less than 5 20.5
5 - 9 20.7
10 - 14 19.9
15 or more 38.9
Have previously worked in a health facility
Yes 27.8
No 72.2
Number of days PM shop is open
7 73.8
6 24.9
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could name a permanent method: tubal ligation (5%) 
and vasectomy (10%). PPMVs were asked which FP 
methods they sold in their shops (Figure 1). PPMVs’ 
knowledge of  FP methods seemed to correspond with 
the type of  FP methods that they sold. The three most 
commonly sold FP methods were the pill (87%), male 
condoms (75%) and injectable contraceptives (59%). 
Almost all PPMVs (92%) provided at least one inject-
able contraceptive service at the pre-test survey. 
Results in Figure 2 show that approximately 60 per-
cent reported they counsel clients on injectable use, sell 
injectable methods or refer clients to the nearest health 
facility for injectable services. Forty-seven percent said 
they administer injectable contraceptives in their shop. 
Figure 3 shows the type of  injectable contraceptive 
methods sold by PPMVs in their shops. PPMVs pri-
marily sold Depo-Provera (58%) and Noristerat (45%). 
Less than two percent reported selling Cyclofem, 

















†Only asked of PPMVs in Bauchi, Cross River, Ebonyi and 
Kaduna
TABLE 2.  PPMV KNOWLEDGE OF CONTRACEPTIVE 
METHODS AT PRETEST SURVEY (N=381)
FIGURE 1 .  CONTRACEPTIVE METHODS SOLD BY PPMVs AT PRETEST SURVEY (N=381)
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PPMVs can administer 
injectable contraceptives 
safely
The observation checklist for PPMV admin-
istration of  DMPA-IM and DMPA-SC was 
conducted in Bauchi, Cross River, Ebonyi 
and Kaduna immediately after the training 
and during the 1- and 6-month monitoring 
visits. The majority of  PPMVs from these 
states demonstrated key steps for safe 
administration of  injectable contraceptives, even six months after the training. Figure 4 shows the proportion 
of  PPMVs who demonstrated the key DMPA-IM administration steps during the post-test and 1-month moni-
toring visit. Results show that at least 75 percent of  PPMVs demonstrated nine key steps for safe administration 
of  DMPA-IM after the training (n=225). There were slight decreases for all but one of  the steps at the 1-month 
monitoring visit (n=196). Only for one DMPA-IM step, pierce top of  vial with sterile needle and fill syringe, was there 
no difference observed from post-test to the 1-month visit (94% compared to 95%). Even though most of  
these decreases were statistically significant, at least 50 percent of  PPMVs demonstrated each of  the nine steps 
at the 1-month monitoring visit. 
PPMVs’ skills improved between the 1- and 6-month monitoring visits. Figure 5 shows changes in the pro-
portion of  PPMVs who demonstrated the key DMPA-IM administration steps at the 1- and 6-month moni-
toring visits. A greater number of  PPMVs demonstrated six of  the nine key DMPA-IM steps compared to the 
1-month observation. For example, the proportion of  PPMVs who checked for the expiration date increased from 
74 percent at the 1-month monitoring visit to 87 percent at the 6-month monitoring visit (p-value ≤0.01). Only 
the DMPA-IM step aspirate needle remained low at the 6-month monitoring visit (56%). Eighty-five percent of  
PPMVs in Bauchi, Cross River, Ebonyi and Kaduna, however, named this step when asked during the 9-month 
follow-up survey (data not shown).
FIGURE 3.  T YPE OF CONTRACEPTIVE METHODS SOLD BY 
PPMVs AT PRETEST SURVEY (N=381)
FIGURE 4.  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-IM ADMINISTRATION STEPS AT 
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FIGURE 5.  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-IM ADMINISTRATION STEPS AT 
1-MONTH MONITORING VISIT (N=196) AND 6-MONTH MONITORING VISIT †
FIGURE 6.  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-SC ADMINISTRATION STEPS AT 
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Figure 6 shows the proportion of  PPMVs who demonstrated the key DMPA-SC administration steps during 
the post-test and 1-month monitoring visit. As seen with DMPA-IM, most PPMVs (79%) demonstrated the 
nine key steps for DMPA-SC administration at post-test. There was a decrease, however, in the proportion of  
PPMVs who demonstrated seven of  the nine key DMPA-SC steps at the 1-month monitoring visit (n=196). 
There were only two DMPA-SC steps, check expiration date (91% to 100%, p-value ≤0.01) and activate the Uniject™ 
(82% to 89%, p-value ≤0.05), where the proportion of  PPMVs who named these steps increased from post-test 
to 1-month monitoring visit.
A greater number of  PPMVs demonstrated six of  the nine key DMPA-SC steps at the 6-month monitoring 
visit compared to the 1-month monitoring visit (Figure 7). For example, when demonstrating the DMPA-SC 
steps, the proportion of  PPMVs who inserted the Uniject straight into skin at a slight downward angle increased from 
49 to 85 percent (p-value ≤0.01). At the 6-month monitoring visit, at least 75 percent of  PPMVs demonstrated 
the key DMPA-SC steps.
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Figure 8 presents the monitoring teams’ observations 
of  PPMVs and their shop during the 1- and 6-month 
monitoring visits. Almost all PPMVs in Bauchi, Cross 
River, Ebonyi and Kaduna were observed having a 
sharps disposal box in their shop at the 1-month and 
6-month monitoring visits (98% each). There was 
an increase in the proportion of  PPMVs who were 
observed properly storing the drugs in their shop 
from 70 percent at the 1-month monitoring visit to 
83 percent at the 6-month monitoring visit (p-value 
≤0.01), and those who kept injectable record form 
21 percent at the 1-month monitoring visit to 50 per-
cent at the 6-month monitoring visit (p-value ≤0.01). 
One reason why only half  of  PPMVs kept injectable 
record forms may have been due to police and regu-
latory harassment, despite being authorized to pro-
vide injectable contraceptives under the study. During 
the monitoring visits, many PPMVs cited police harassment for why they did not keep up-to-date records. 
Regulatory and police representatives periodically visit patent medicine shops to ensure PPMVs are not selling 
unauthorized commodities, or for extortion. This may explain why some PPMVs reported that they did not 
keep records of  their injectable contraceptive services. 
Most PPMVs administered injectable contraceptives to at least one client monthly. Eighty-seven percent of  
PPMVs in all six states (n=318) reported they had administered an injectable contraceptive to at least one 
client in the 30 days preceding the 3-month follow-up survey and 92 percent reported they had administered 
an injectable contraceptive to at least one client in the 30 days preceding the 9-month follow-up survey. At the 
9-month survey, the average number of  injections provided in the previous 30 days was 2.4 for DMPA-IM, 
1.3 for NET-EN and less than 1 for DMPA-SC (data not shown). No adverse events were reported over the 
course of  the study.
FIGURE 7.  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-SC ADMINISTRATION STEPS AT 
1-MONTH AND 6-MONTH MONITORING VISITS †
FIGURE 8.  COMPARISON OF MONITORING TEAM 
OBSERVATIONS OF PPMVs’  PRACTICES AT 
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There was no difference in knowledge and skills between PPMVs with and 
without previous health facility experience
PPMVs were asked a series of  unprompted questions to ascertain their knowledge on injectable contraceptives. 
Specifically, PPMVs were asked about the knowledge needed for counseling (side effects), screening (exclu-
sionary health conditions), and providing injectable contraceptives (when a woman can start the injectable, 
post-administration instructions for clients, and needle safety practices). The results in Table 3 show there 
were no differences between those who had and who had not previously worked in a health facility for most of  
the knowledge indicators. At the post-test survey, there were statistically significant differences in knowledge 
for only 8 of  41 indicators. For example, 76 percent of  PPMVs who had worked in a health facility named 
dizziness as a side effect compared to 62 percent of  PPMVs who had not worked in a health facility (p-value ≤0.05). 
Interestingly, PPMVs who had not previously worked in a health facility demonstrated higher knowledge for 
two of  those eight indicators. Forty percent of  PPMVs who had not worked in a health facility named current or 
history of  stroke and 35 percent named liver tumor as exclusionary health conditions compared to only 26 percent 
and 20 percent of  PPMVs who had worked in a health facility (p-value ≤0.05; p-value ≤0.01). There were no 
differences in knowledge of  the nine method characteristic indicators (reinjection frequency, injection device, 
and administration location on the body) for DMPA-IM, NET-EN and DMPA-SC between the two groups 
(data not shown).
TABLE 3.  COMPARISON OF PPMV INJECTABLE KNOWLEDGE AMONG THOSE WHO HAD AND HAD NOT 
PREVIOUSLY WORKED IN A HEALTH FACILIT Y,  POST-TEST SURVEY †
PPMVs who had previously 
worked in a facility (n=95)
PPMVs who had not previously 
worked in a facility (n=203)
Percentage
What are the common side effects of the injectable?
Change in menstruation 96.8 91.6
Headache 85.3 84.2
Weight gain 64.2 55.7
 Dizziness* 75.8 62.1
Delayed return to fertility 27.4 24.6
Temporary mild/moderate skin irritation** 40.0 18.7
Decrease in sex drive 22.1 21.2
Under what health conditions should a woman NOT be provided the injectable?
High blood pressure (160/100)* 82.1 70.4
History of breast cancer 65.3 70.0
 Diabetes 61.1 62.6
Current/history of stroke or ischaemic heart disease* 26.3 40.4
Multiple risk factors for cardiovascular disease 40.0 37.0
Liver tumor** 20.0 35.0
Unexplained vaginal bleeding 38.9 32.0
Breastfeeding up to 4/6‡ weeks postpartum 25.3 18.7
Rheumatic disease 15.8 19.7
Migraines with aura worsening with injectable use 14.7 16.3
Deep vein thrombosis 7.4 11.8
When can a woman start the injectable method?
When she is not pregnant 67.4 56.7
4/6‡ weeks after childbirth 66.3 63.1
Within 1st 7 days of a menstrual cycle w/out back-up method 31.6 30.1
con’t on next page
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*p-value ≤0.05; **p-value ≤0.01
†Comparisons used for PPMVs in all states except Oyo due to respondent ID error
‡ The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained 
using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
PPMVs who had previously 
worked in a facility (n=95)
PPMVs who had not previously 
worked in a facility (n=203)
Percentage
After 1st 7 days of a menstrual cycle w/ back-up method 27.4 37.0
Immediately after a miscarriage or abortion* 29.5 19.2
Immediately after stopping another method* 30.5 17.7
What instructions should be provided to women after administering the injection?
When to return for next injection 90.5 96.1
Do not rub the injection site 70.5 60.1
Provide information about possible side effects 64.1 58.1
Go to health facility if concerns/questions about the method 10.5 9.4
Go to health facility if any significant changes in health 17.9 17.2
Go to health facility if suspicion about pregnancy 11.6 7.9
What are the ways to handle needles/syringes safely?
Don’t touch the needles 75.8 72.9
Don’t recap the needle 71.6 68.0
Discard needle immediately after use** 80.0 61.6
Ensure sharps are disposed of in sharps box 72.6 68.5
Don’t overfill sharps box 42.3 35.5
What precautions should be taken to prevent infection from a needle stick injury?
Wash hands with soap and water immediately 75.8 69.0
Use sharps box for needles and sharps 60.0 56.2
Handle needles carefully 63.2 58.1
What should be done in the case of a needle stick injury?
Wash wound with soap and water 85.3 86.2
Ensure nothing is put on wound site after cleaning it 25.3 17.7
Apply plaster bandage to wound site 11.6 5.4
TABLE 4.  COMPARISON OF PPMV INJECTABLE KNOWLEDGE AMONG THOSE WHO HAD AND HAD NOT 
PREVIOUSLY WORKED IN A HEALTH FACILIT Y,  9-MONTH FOLLOW-UP SURVEY †
PPMVs who had previously 
worked in a facility (n=84)
PPMVs who had not previously 
worked in a facility (n=181)
Percentage
What are the common side effects of the injectable?
Change in menstruation 90.5 90.6
Headache 85.7 81.2
Weight gain 81.0 71.8
Similar trends were observed at the 9-month follow-up survey (Table 4). Results shows that there were no 
significant differences in (a) knowledge of  injectable side effects, (b) how to handle needles safely, (c) how to 
prevent infection from a needle stick injury, or (d) what should be done in case of  a needlestick injury among 
those who had and had not previously worked in a health facility. Of  the 41 knowledge indicators, PPMVs who 
had previously worked in a health facility demonstrated higher knowledge for only four of  those indicators: 
(1) diabetes as an exclusionary health condition; (2) a woman can start the injectable within first seven days of  her 
menstrual cycle without a back-up method; (3) when to return for the next injection; and, (4) provide information about possible 
side effects as post-administration information for clients.
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PPMVs who had previously 
worked in a facility (n=84)
PPMVs who had not previously 
worked in a facility (n=181)
Percentage
 Dizziness 57.1 57.5
Delayed return to fertility 17.9 17.7
Temporary mild/moderate skin irritation 34.5 24.9
Decrease in sex drive 23.8 20.4
Under what health conditions should a woman NOT be provided the injectable?
High blood pressure (160/100)* 67.9 63.5
History of breast cancer 52.4 57.5
 Diabetes** 82.1 63.0
Current/history of stroke or ischaemic heart disease 33.3 27.6
Multiple risk factors for cardiovascular disease 22.6 28.7
Liver tumor 29.8 27.1
Unexplained vaginal bleeding 31.0 27.1
Breastfeeding up to 4/6‡ weeks postpartum 29.8 24.9
Rheumatic disease 4.8 8.9
Migraines with aura worsening with injectable use 22.6 16.6
Deep vein thrombosis 16.7 15.5
When can a woman start the injectable method?
When she is not pregnant 82.1 72.4
4/6‡ weeks after childbirth 66.7 58.0
Within 1st 7 days of a menstrual cycle w/out back-up method** 54.8 37.6
After 1st 7 days of a menstrual cycle w/ back-up method 26.2 37.0
Immediately after a miscarriage or abortion 23.8 18.8
Immediately after stopping another method 15.5 12.7
What instructions should be provided to women after administering the injection?
When to return for next injection* 96.4 88.4
Do not rub the injection site 72.6 63.0
Provide information about possible side effects* 76.2 63.0
Go to health facility if concerns/questions about the method 3.6 9.9
Go to health facility if any significant changes in health 26.2 20.1
Go to health facility if suspicion about pregnancy 13.1 6.6
What are the ways to handle needles/syringes safely?
Don’t touch the needles 81.0 78.5
Don’t recap the needle 81.0 79.0
Discard needle immediately after use 54.8 58.6
Ensure sharps are disposed of in sharps box 71.4 75.1
Don’t overfill sharps box 17.9 18.8
What precautions should be taken to prevent infection from a needle stick injury?
Wash hands with soap and water immediately 81.0 68.0
Use sharps box for needles and sharps 62.4 67.9
Handle needles carefully 78.6 71.8
What should be done in the case of a needle stick injury?
Wash wound with soap and water 82.1 85.6
Ensure nothing is put on wound site after cleaning it 28.6 21.0
Apply plaster bandage to wound site 15.5 15.5
*p-value ≤0.05; **p-value ≤0.01
†Comparisons used for PPMVs in all states except Oyo due to respondent ID error
‡ The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained 
using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
20             OCTOBER 2018
Figures 9, 10, 11 and 12 show the differences in PPMV demonstration of  key DMPA-IM and DMPA-SC 
administration steps between those with and without health facility experience at the post-test and 6-month 
monitoring visits. As seen with the knowledge indicators, PPMVs without health facility experience demon-
strated comparable skills for DMPA-IM and DMPA-SC administration to those with health facility experience 
at both time points. For example, only for two DMPA-IM steps, withdraw contents and expel air from the syringe and 
aspirate needle, and one key DMPA-SC step, check expiration date, did a significantly higher proportion of  PPMVs 
with health facility experience demonstrate these steps compared to those without health facility experience 
at the post-test observation (Figures 9 and 10). At the 6-month monitoring visit, however, there were no 
differences for eight of  the nine key DMPA-IM steps and seven of  the nine DMPA-SC steps. For the steps 
where there were significant differences, a higher proportion of  PPMVs without health facility experience 
demonstrated these steps (dispose of  needle for DMPA-IM and guide client to select injection site and activate Uniject for 
DMPA-SC) compared to those with health facility experience (Figures 11 and 12).
FIGURE 9.  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-IM ADMINISTRATION STEPS AMONG 
THOSE WHO HAD AND HAD NOT PREVIOUSLY WORKED IN A HEALTH FACILIT Y,  POST-TEST
FIGURE 10.  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-SC ADMINISTRATION STEPS AMONG 
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†Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
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FIGURE 11 .  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-IM ADMINISTRATION STEPS AMONG 
THOSE WHO HAD AND HAD NOT PREVIOUSLY WORKED IN A HEALTH FACILIT Y,  6-MONTH MONITORING VISIT
FIGURE 12.  COMPARISON OF PPMV DEMONSTRATION OF KEY DMPA-SC ADMINISTRATION STEPS AMONG 
THOSE WHO HAD AND HAD NOT PREVIOUSLY WORKED IN A HEALTH FACILIT Y,  6-MONTH MONITORING VISIT
PPMVs knowledge of injectable contraceptive characteristics was higher 
after the training and was retained nine months after the training
Knowledge increased from the pretest to post-test survey
PPMVs were asked a series of  unprompted questions to ascertain their knowledge on injectable contraceptives 
during the pre-, post- and 9-month surveys. Significant increases in PPMVs’ knowledge related to counseling, 
screening and administration of  the injectable contraceptive method were observed on 47 of  50 knowledge 
indicators from the pretest to post-test survey. Knowledge doubled for 32 indicators and increased by at least 
half  for eight indicators. Despite these increases, knowledge remained below 50 percent for 21 indicators at the 
post-test survey. 
Figure 13 shows PPMV knowledge of  seven common side effects of  the injectable method at the pretest and 
post-test surveys. At the pretest survey, less than one-third of  PPMVs spontaneously named headache (23%), 
weight gain (32%), dizziness (19%), delayed return to fertility (8%), temporary skin irritation (1%) or decrease in sex drive 
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†Observations used for PPMVs in Bauchi, Cross River, Ebonyi and Kaduna
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(2%) as common side effects of  the injectable method. At the post-test survey, knowledge on all seven common 
side effects increased significantly. Larger increases were seen for: (1) change in menstruation from 64 percent to 93 
percent; (2) headache from 23 percent to 79 percent; (3) weight gain from 32 percent to 60 percent; and (4) dizziness 
from 19 percent to 56 percent. For the remaining three side effects, the percentage point increases in knowledge 
at post-test were not as large and knowledge remained low at approximately 20%.
Figure 14 shows that pretest and post-test survey results of  11 exclusionary health conditions of  the injectable 
contraceptive. At the pretest survey, 41 percent of  PPMVs named high blood pressure as an exclusionary health 
condition. Fewer spontaneously named any of  the other health conditions8, ranging from 19 percent saying dia-
betes to 3 percent migraines with aura or deep vein thrombosis. At the post-test survey, knowledge on all 11 exclusionary 
health conditions increased significantly, yet eight health conditions were mentioned by fewer than 50 percent.
8 For the purposes of  the study, PPMVs were authorized to administer clients were in category one based on the WHO Medical Eligibility 
Criteria.
FIGURE 13.  KNOWLEDGE COMPARISONS OF SEVEN COMMON SIDE EFFECTS OF THE INJECTABLE AT 
PRETEST AND POST-TEST SURVEYS †
FIGURE 14.  KNOWLEDGE COMPARISONS OF 11 EXCLUSIONARY HEALTH CONDITIONS OF THE INJECTABLE 
AT PRETEST AND POST-TEST SURVEYS †
64.0
92.8
†Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.





























†Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
‡ The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained using the 6-week standard and PPMVs in the additional
four states were trained using the 4-week standard.
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Figure 15 presents PPMVs’ knowledge of  when a woman can begin the injectable. At the pretest survey, only 
33 percent of  PPMVs said if  she is not pregnant and 19 percent said within the first seven days of  her menstrual cycle 
without a back-up method for when a woman can start the injectable. At the post-test survey, these two indica-
tors increased to 58 percent and 41 percent, respectively. Statistically significant increases in knowledge were 
observed for all knowledge indicators in Figure 15 except after first seven days of  a menstrual cycle with back-up method. 
After the training, few PPMVs spontaneously recalled that the injection could be used immediately after a miscar-
riage or abortion (18%) or immediately after stopping another method (18%).
Figure 16 shows PPMV responses to the information that should be offered to clients after receiving an 
injectable. Across the six indicators at the pretest survey, the proportion of  PPMVs who knew this information 
ranged from 40 percent for when to return for the next injection to 5 percent for going to health facility for significant 
changes in health. At the post-test survey, nearly all (92 %) of  PPMVs knew to tell their client when to return for their 
next injection. Roughly two-thirds (66%) of  PPMVs knew to tell their client not to rub the injection site and more than 
half  (60 %) knew to provide information about possible side effects. Fewer PPMVs, however, said that clients should 
go to the health facility if  significant changes in health (15%), go to health facility if  concerns/questions about methods (9%), or 
to go to the health facility if  suspicion of  pregnancy (7%). When comparing these results to client responses in Figure 
26, 91 percent of  clients reported the PPMV told them what to do if  they had a problem with the injectable 
at their first injection (n=561). Eighty-seven percent of  clients reported they were instructed to return to the 
PPMV if  they experienced any problems (data not shown).
Despite knowledge gains for 29 of  the 30 indicators listed in Figures 13-16, knowledge remained low for some 
indicators. However, most PPMVs (86%) in Bauchi, Cross River, Ebonyi, and Kaduna reported using job aids 
with their clients, suggesting PPMVs may refer to job aids to assist in remembering long lists of  information 
(e.g. side effects and exclusionary health conditions) when providing injectable contraceptive services. 
PPMVs were also asked about the characteristics of  different injectable methods as shown in Figure 17. Results 
show that key knowledge of  DMPA-IM, DMPA-SC, and NET-EN9 was significantly higher at the post-test 
9 Only PPMVs in the additional four states were asked questions about NET-EN.
FIGURE 15.  KNOWLEDGE COMPARISONS OF WHEN A WOMAN CAN START THE INJECTABLE AT 






†Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
‡The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states 
were trained using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
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FIGURE 16.  KNOWLEDGE COMPARISONS OF POST-ADMINISTRATION INSTRUCTIONS AT PRETEST 
AND POST-TEST SURVEYS †
FIGURE 17.  KNOWLEDGE COMPARISONS OF KEY INJECTABLE METHOD CHARACTERISTICS AT 
PRETEST AND POST-TEST SURVEYS †
†Post-training survey asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
*p-value ≤0.05; **p-value ≤0.01
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†Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
‡Asked of PPMVs in Bauchi, Cross River, Ebonyi and Kaduna only 
*p-value ≤0.05; **p-value ≤0.01
than at the pretest survey. The greatest increases in knowledge were observed for DMPA-SC because a small 
proportion of  PPMVs at pretest (5 %) knew about this method (data not shown). At the post-test survey, over 
89 percent of  PPMVs correctly named the (a) reinjection frequency, (b) at least one location on the body where 
the injectable can be administered, and (c) the device used to administer each of  the three injectable methods. 
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TABLE 5.  KNOWLEDGE COMPARISONS OF NEEDLE SAFET Y PRACTICES AT PRETEST 
AND POST-TEST SURVEYS †
Pre-test (n=381) Post-test (n=377)
Percentages
What are the ways to handle needles safely
Don’t touch the needle** 48.6 74.0
Don’t recap the needle** 29.7 65.8
Discard needle immediately after use** 35.7 71.9
Ensure sharps are disposed of in sharps box** 32.6 69.8
Don’t overfill sharps box** 9.2 36.1
What precautions should be taken to prevent infection from needle stick injuries
Wash hands with soap and water immediately 
before and after administering the injectable** 30.5 73.5
Use sharps box for needles and sharps** 35.7 59.7
Handle needles carefully* 50.9 62.3
What should be done in the case of a needles stick injury
Wash wound with soap and water** 36.8 82.5
Ensure nothing is put on wound site after cleaning it 22.6 17.8
Apply plaster bandage to wound site** 23.6 7.9
*p-value ≤0.05; **p-value ≤0.01
†Post-training survey asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
To understand PPMVs knowledge of  needle safety practices, PPMVs were asked: (1) how to handle needles 
safely; (2) how to prevent infection from a needle stick injury; and (3) what to do in the event of  a needle stick 
injury. Table 5 presents these results. For most of  the indicators, fewer than 50 percent of  PPMVs displayed 
knowledge before the training, but the percentage increased significantly after the training. For example, 72 
percent of  PPMVs at the post-test survey identified don’t recap needles as one way to handle needles safely com-
pared to 36 percent at the pretest survey (p-value ≤0.01). Seventy-four percent at the post-test survey identified 
wash hands before and after administration to prevent infection compared to 31 percent at the pretest survey (p-value 
≤0.01). The percentage of  PPMVs with knowledge remained low at the post-test survey for ensure nothing is in 
the wound site (18 %) and decreased from 24 percent to 8 percent for apply plaster bandage to the wound site.
Knowledge retention from post-test to 9-month follow-up survey
PPMVs retained knowledge of  injectable contraceptive characteristics nine months after the training. Among 
the 50 indicators used to measure knowledge, from the post-test survey to the 9-month follow-up survey, 
knowledge increased for 13 of  50 indicators and was retained for 29 of  50 indicators. For 21 indicators, less 
than 50 percent of  PPMVs displayed knowledge at the post-test survey.
Figures 18, 19, 20 and 21 show knowledge comparisons between the post-test and 9-month surveys for 
common side effects, exclusionary health conditions, when a woman can begin the injectable and post-adminis-
tration instructions. Results show that there were no significant differences for most of  the indicators between 
the post-test and 9-month follow-up surveys. In some cases, knowledge increased. For example, in Figure 18 
knowledge of  weight gain as a side effect increased from 60 percent at the post-test to 74 percent at the 9-month 
survey (p-value ≤0.01). In Figure 20, PPMVs who said a woman can start the injectable method when she is not 
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pregnant increased from 58 percent to 73 percent, and within the first seven days of  her menstrual cycle without a back-up 
method increased from 41 percent to 55 percent (p-value ≤0.05). 
There were few decreases in knowledge between the post-test and 9-month surveys. In Figure 18, fewer 
PPMVs identified delayed return to fertility as a side effect at the 9-month survey (15 %) compared to the post-test 
survey (23 percent, p-value ≤0.01). In Figure 19, fewer PPMVs named the following exclusionary health con-
ditions at the 9-month survey compared to the post-test: history of  breast cancer (65% vs. 44%), liver tumor (30% 
vs. 23%), and rheumatic disease (19% vs. 6%).
Figure 22 shows that PPMVs’ knowledge of  method-specific characteristics was the same between the post-
test and 9-month surveys for six of  the nine indicators. PPMVs’ knowledge of  the correct injection device used 
for DMPA-IM (syringe and needle) and for DMPA-SC (Uniject) increased from the post-test survey to 9-month 
survey. For example, 100 percent of  PPMVs correctly named Uniject as the injection device for DMPA-SC 
compared to 93 percent at the post-test survey. Only for the DMPA-SC reinjection frequency (13 weeks) was 
there a decrease in knowledge between the 9-month and post-test survey. Still, 92 percent of  PPMVs correctly 
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FIGURE 18.  KNOWLEDGE COMPARISONS OF SEVEN COMMON SIDE EFFECTS OF THE 
INJECTABLE AT POST-TEST † AND 9-MONTH SURVEYS
FIGURE 19.  KNOWLEDGE COMPARISONS OF 11 EXCLUSIONARY HEALTH CONDITIONS OF THE INJECTABLE AT 






†Post-training surveyss asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
‡The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states were trained using the 6-week standard and PPMVs in the additional four states were trained 
using the 4-week standard.
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FIGURE 20.  KNOWLEDGE COMPARISONS OF WHEN A WOMAN CAN START THE INJECTABLE AT THE 






†Post-training surveyss asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
‡The WHO guidelines for injectable use and breastfeeding were updated during the study’s implementation. PPMVs in the first two states 
were trained using the 6-week standard and PPMVs in the additional four states were trained using the 4-week standard.
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FIGURE 21 .  KNOWLEDGE COMPARISONS OF POST-ADMINISTRATION INSTRUCTIONS AT THE POST-
TEST † AND 9-MONTH SURVEYS
†Post-training survey asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
*p-value ≤0.05; **p-value ≤0.01
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Do not rub the injection site
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Table 6 presents changes in PPMVs’ knowledge of  needle safety measures from the post-test and 9-month 
surveys. PPMVs’ knowledge increased for many of  the needle safety measures: a higher proportion of  PPMVs 
named wash hands with soap and water (72% compared to 60%, p-value ≤0.01) and handle needles carefully (80% 
compared to 62%, p-value ≤0.01) as ways to prevent infection from needle stick injury at the 9-month survey. 
Increases were also seen for three of  five indicators to handle needles safely. Only for two indicators, discard 
needle immediately after use and don’t overfill the sharps box, did the percentage of  PPMVs with knowledge decrease 
from the post-test to 9-month survey (20 and 21 percentage point decrease, respectively).
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FIGURE 22.  KNOWLEDGE COMPARISONS OF KEY INJECTABLE METHOD CHARACTERISTICS AT POST-
TEST † AND 9-MONTH SURVEYS
TABLE 6.  KNOWLEDGE COMPARISONS OF NEEDLE SAFET Y PRACTICES AT POST-TEST † 
AND 9-MONTH SURVEYS
Post-test (n=377) 9-month (n=343)
Percentages
What are the ways to handle needles safely
Don’t touch the needle** 74.0 83.9
Don’t recap the needle** 65.8 84.3
Discard needle immediately after use** 71.9 51.9
Ensure sharps are disposed of in sharps box** 69.8 79.9
Don’t overfill sharps box** 36.1 14.9
What precautions should be taken to prevent infection from needle stick injuries
Wash hands with soap and water immediately before 
and after administering the injectable 73.5 78.4
Use sharps box for needles and sharps** 59.7 72.3
Handle needles carefully** 62.3 79.9
What should be done in the case of a needle stick injury
Wash wound with soap and water* 82.5 88.1
Ensure nothing is put on wound site after cleaning it 17.8 22.1
Apply plaster bandage to wound site 7.9 11.9
*p-value ≤0.05; **p-value ≤0.01
†Comparisons used for PPMVs in all states except Oyo due to respondent ID error
100%75%50%25%0%DMPA-IM
Injection device (syringe/needle)
Injection frequency (3 months/13 weeks)
Injection location (deltoid or buttocks)
NET-EN ‡
Injection device (syringe/needle)
Injection frequency (2 months/8 weeks)
Injection location (deltoid or buttocks)
DMPA-SC
Injection device (uniject)
Injection frequency (3 months/13 weeks)
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†Post-training surveys asked 1 month after training in the 1st two states and immediately after the training in the additional four states.
‡Asked of PPMVs in Bauchi, Cross River, Ebonyi and Kaduna only
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Client characteristics at first injection 
and contraceptive use dynamics over 
time
A total of  561 clients were contacted by telephone and 
surveyed within five days of  receiving their first injec-
tion from a trained PPMV. Table 7 presents client char-
acteristics at the time of  their first injection. The median 
age of  these clients was 30 years (data not shown), with 
more than half  between the ages of  25 and 39. Most 
had at least some schooling (94%), and more than half  
(70%) had a secondary education or higher. Most clients 
were married or living with a partner (92%) and had at 
least one child (94%). One-third (33%) did not want to 
have any additional children, while slightly more than 
one-quarter (28%) wanted to wait at least two years 
before having their next child. Sixty percent of  clients 
were employed. Forty percent of  respondents had gone 
to the same PPMV for injectable services at least once 
before this visit (data not shown).
Figure 23 presents the outcome of  clients’ first visit to 
a trained PPMV for injectable contraceptive services. 
More than half  had been using a contraceptive method 
before this visit: 40 percent continued with the injectable 
method and 19 percent switched from a different con-
traceptive method. Forty-two percent of  clients began 
a new episode of  use.10 Of  the 40 percent (n=224) 
who continued using the injectable method, 65 percent 
received DMPA-IM, 18 percent received NET-EN, and 
15 percent received DMPA-SC. Two percent did not 
know which method they received.
Clients were asked why they chose PPMVs for inject-
able contraceptive services rather than going elsewhere 
(Figure 24). While clients listed multiple reasons, con-
venient location was the most commonly cited reason 
(61%). The next most commonly named reasons 
included anonymous care (32%), knowing the PPMV 
personally (32%), and no waiting time (31%).
At each follow-up survey, clients who continued using 
an injectable contraceptive were asked whether they had 
experienced side effects in the three months preceding 
10 Clients who began a new episode of  use is defined as a client who 
was not using a contraceptive method the day before their first visit 
to a trained PPMV.
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†Percentages may not add to 100% due to missing data
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the survey. At the time of  their second injec-
tion, one in five clients (20%) experienced side 
effects in the preceding three months (n=382). 
By the third injection, only 12 percent of  cli-
ents had experienced side effects (n=327, data 
not shown). 
Clients who had experienced side effects were 
asked whether they reported those side effects 
to a PPMV or to another provider (Figure 
25). At each time point, over 70 percent of  
clients said that they reported the side effect 
to the PPMV. The percentage who reported a 
side effect to a health care provider increased 
from six percent to 16 percent between the 
second and third injection. Twenty-eight per-
cent of  clients at their second interview and 24 percent at their third interview did not report their side effects 
to a PPMV or other health care provider.
FIGURE 25.  REPORTING OF SIDE EFFECTS TO PPMVs OR OTHER 
PROVIDERS, AMONG CONTINUING INJECTABLE CLIENTS WHO 
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FIGURE 23.  OUTCOME OF CLIENT’S FIRST VISIT TO A 
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FIGURE 24.  CLIENTS’  REASONS FOR CHOOSING PPMVS FOR INJECTABLE CONTRACEPTIVE SERVICES AT FIRST 
INJECTION BY A TRAINED PPMV (N=561) †
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FIGURE 26.  QUALIT Y OF CARE RECEIVED AT FIRST INJECTION BY TRAINED PPMVs (N=561)
Clients reported receiving quality family planning counseling and were 
satisfied with injectable contraceptive services received from PPMVs
To examine the quality of  care received from PPMVs, clients were asked whether they received specific coun-
seling information at each injection. Quality of  care results are presented in Figure 26. Over 90 percent of  
clients reported receiving information on 8 of  9 counseling items at the first injection visit. Fewer clients (82%) 
were told about what actions to take to resolve a side effect. 
Figure 27 presents quality of  care received by clients at their second and third injections. High quality of  care 
continued among clients who returned to PPMVs for their second and third injections. Reported information 
received was high for all items at both the second and third injection. Over 90 percent of  clients were told when 
to return for follow-up, felt their information would be kept confidential, felt comfortable asking questions, 
were told what to do if  they have problems with the injectable, and were told about the potential side effects 
of  the injectable.
100%75%50%25%0%
Told you when to return for follow-up
Told you what to do if you have problems with the injectable
Told you about potential side effects of injectables










FIGURE 27.  QUALIT Y OF CARE RECEIVED BY CONTINUING CLIENTS AT FOLLOW-UP INJECTIONS BY 
TRAINED PPMVs
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Comparing responses from Figure 26 and 27, clients reported high quality of  care from the first visit, which 
continued to subsequent visits. Though fewer clients were given suggestions to resolve problems due to side 
effects, nearly 90 percent of  respondents received this information at their second injection. 
Figure 28 presents additional 
aspects of  clients’ experiences 
receiving injectable services 
from PPMVs. Across all survey 
times, nearly all respondents 
reported they would recommend 
the PPMV to a friend and that 
they themselves would return 
for injectable services. Clients in 
the additional four states were 
asked whether they found inject-
able contraceptive services from 
PPMVs affordable. Seventy-two 
percent of  PPMVs in the addi-
tional four states felt their inject-
able services were affordable at 
their first injection. This increased 
to nearly 90 percent at the second 
injection (data not shown).
Clients who discontinued the injectable contraceptive did so for reasons 
unrelated to PPMV service quality
Based on lessons learned in Nasarawa and Oyo, clients in Bauchi, Cross River, Ebonyi and Kaduna who 
discontinued the injectable or had not received their most recent injection were asked why they had not gone 
back or stopped using the method (Table 8). At the time of  their second injection, 18 percent of  respondents 
were lost to follow-up (n=52), 57 percent continued using their same injectable method (n=169), 24 percent 
had discontinued the method or not received their most recent injection on time (n=71), and one percent 
(n=2) had switched to another method (pill and female condoms). Among the 26 percent (n=73) who had 
discontinued, had not received their most injection or switched methods, the top three reasons why clients 
stopped using the injectable before receiving their second injection were: not having time to go back for their 
injection (26%); side effects (19%); and their partner (12%). 
At the time of  the third injection, 27 percent were lost to follow-up (n=78), 51 percent had continued their 
injectable method (n=150), 20 percent had discontinued their injectable method (n=60), and 2 percent (n=6) 
had switched to another method (pill, implant, or condom). Among those who stopped using the injectable or 
PPMV injectable services before their scheduled third injection (n=66), the top three reasons were: didn’t have 
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FIGURE 28.  OTHER ASPECTS OF CONTINUING CLIENTS’  VISITS 
TO TRAINED PPMVS FOR INJECTABLE CONTRACEPTIVE SERVICES
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Didn’t have time to go back for most recent injection 26.0 21.2
Side effects 19.2 18.2
Wanted to become pregnant 12.3 19.7
Stopped method because of partner 12.3 13.6
Partner or client was traveling 9.6 1.5
Client was pregnant 5.5 9.1
Lack of money 6.8 0.0
Forgot to go back 5.5 0.0
Didn’t like the method/wanted to stop 0.0 10.6
Other 2.7 6.1
†Only asked of clients in Bauchi, Cross River, Ebonyi and Kaduna
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Discussion
The results of  this study show that many PPMVs were providing injectable contraceptives to clients who were 
voluntarily seeking these services from them, which is consistent with findings from previous studies (Ajuwon 
et al., 2013; NPC and ICF, 2014). Results also show that it is feasible for PPMVs to administer injectable con-
traceptive services with training, mentorship and support. The study also demonstrated that the majority of  
clients were satisfied with the services they received from PPMVs. 
PPMVs can safely provide injectable contraceptives
After receiving a training, almost all PPMVs demonstrated the key steps for administering injectable contracep-
tives and this skill was retained over time. At the 6-month monitoring visit, for example, most PPMVs demon-
strated all the key steps for safe DMPA-IM and DMPA-SC administration in front of  a certified FP Master 
Trainer. Fewer PPMVs (56%) demonstrated aspirate needle when observed at the 6-month monitoring visit. 
When asked to name the DMPA-IM administration steps in the 9-month follow-up survey, however, 85 percent 
named this step (data not shown). One reason why aspirate needle was low during the observations could have 
been because it is difficult to demonstrate this without a real client. Results from the survey, however, suggest 
that many PPMVs knew this was a key DMPA-IM administration step. Still, this DMPA-IM step should be 
emphasized in future trainings to ensure PPMVs understand its importance and do it routinely. 
Almost all PPMVs in Bauchi, Cross River, Ebonyi and Kaduna (observation data were not collected in Oyo 
and Nasarawa) were observed having the sharps disposal box in their shops, suggesting that PPMVs will dis-
pose of  sharp waste safely when provided with disposal boxes. Even though PPMVs in this study were linked 
to local government headquarters with incineration facilities for proper disposal, the study did not assess how 
consistently PPMVs were taking the sharps boxes to the incineration sites. Future programmatic and research 
activities may look to explore barriers to PPMVs consistent disposal of  sharps at incineration locations. 
There was no difference in knowledge and skills between PPMVs with and 
without previous health facility experience
Some argue that PPMVs who previously worked in a health facility would be better equipped to provide 
injectable contraceptive services to clients. After the training, however, PPMVs without previous health facility 
experience demonstrated the same knowledge (and higher knowledge for two indicators) for 44 of  the 50 indi-
cators at the post-test survey and for 46 of  the 50 indicators at the 9-month follow-up survey. Furthermore, 
PPMVs without health facility experience demonstrated all the same steps required for safe administration of  
DMPA-IM and DMPA-SC at the post-test and 6-month monitoring visit. These results strongly suggest that 
PPMVs without previous health facility experience perform as well as PPMVs with health facility experience 
when provided with proper training. Considering that only 28 percent of  PPMVs in our study had previously 
worked in a health facility, permitting all PPMVs to provide injectable contraceptives (given they can read and 
write) could greatly improve access to FP and injectable services to communities across Nigeria. 
PPMVs’ knowledge of injectable contraceptive characteristics was high after 
the training and was retained nine months after the training
Although most PPMVs were already providing some type of  injectable contraceptive service, PPMVs’ knowl-
edge of  injectable contraceptive methods was low before the training. Across all six states, PPMVs’ knowledge 
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of  injectable contraceptive characteristics increased immediately after the training and was retained nine months 
later. This suggests that PPMVs can learn from a standardized training that offers information about inject-
able characteristics and skills to administer injectable services. PPMVs’ learned and retained some knowledge 
better than others. For example, less than a quarter identified either delayed return to fertility (23%), temporary 
skin irritation (21%) or decrease in sex drive (18%) as common injectable side effects at the post-test survey. 
Similarly, few PPMVs named breastfeeding (21%), rheumatic disease (19%), migraines with aura (19%), or deep 
vein thrombosis (13%) as exclusionary health conditions at the post-test survey. These questions were based on 
spontaneous responses, so recall of  certain side effects and exclusionary health conditions may be better than 
others. In this study, PPMVs were given several job aids: the MEC wheel, BCS+, and the FHI 360 screening 
checklist. In Bauchi, Cross River, Ebonyi and Kaduna (data not collected from PPMVs in Nasarawa and Oyo) 
86 percent of  PPMVs reported that they used one or more of  these job aids with their clients. This suggests 
that the data collection methodology used in this study may not have accurately capture PPMVs knowledge and 
behaviors vis-à -vis what they tell clients. Most clients reported being told about side effects, which may reflect 
the PPMVs’ use of  the job aids. This also suggests that it is important to consider how these areas of  knowl-
edge can be improved: is it linked to number of  clients seen or should it be emphasized in future trainings? 
These areas need to be better explored in future implementation activities. 
Clients reported receiving quality family planning counseling and were 
satisfied with injectable contraceptive services received from PPMVs
Of  the 561 clients interviewed, 42 percent were not using a method on the day before receiving their first injec-
tion from a trained PPMV (although some may have had previous episodes of  using contraception). This sug-
gests that PPMVs have the potential to broaden contraceptive availability to new contraceptive users. Results 
from the client surveys complement findings from the PPMV surveys and demonstrations that suggest PPMVs 
can learn and apply FP counseling and injectable contraceptive knowledge with proper support. Over 80 per-
cent of  clients reported receiving information on 11 quality of  care indicators and were satisfied with injectable 
services received. The clients also felt that PPMVs were knowledgeable about injectable contraceptives and 
PPMVs gave them an opportunity to ask questions. Consequently, almost all clients were willing to return to the 
same PPMV for future injectable services and would refer others to the PPMV for injectable services. 
Clients who discontinued the injectable contraceptive did so for reasons 
unrelated to PPMV service quality
Among clients who stopped using the injectable, most did so because of  their desire to become pregnant. Of  
the few women who experienced side effects, almost all discussed the side effects they experienced with their 
PPMV. These findings suggest that women are willing to return to a PPMV to discuss issues that they may face 
with the injectable contraceptive method.
Strengths & limitations of the study
There were several limitations of  this study. First, it would have been useful to implement surveys to healthcare 
providers in the public sector to see how PPMVs knowledge compared to staff  who are currently offering these 
services. Second, there were some challenges in reaching clients over time in Nasarawa and Oyo. Some clients 
had moved outside of  the study sites or did not have steady access to a telephone/cell phone. In Bauchi, Cross 
River, Ebonyi, and Kaduna states, owning a phone or confirming regular access to a phone was added to the 
client eligibility criteria, however similar difficulties were encountered. 
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Third, while there exists some demand for injectable contraceptive services by PPMVs, the average number of  
clients received per month was too low to include observations of  client-provider interactions. Demand may 
also impact PPMVs knowledge and skills. Future interventions should include a demand generation component. 
Fourth, PPMVs record keeping was low. Fifty percent of  PPMVs observed in Bauchi, Cross River, Ebonyi and 
Kaduna had completed the record form provided by the study team at the 6-month monitoring visit. Record 
keeping is important because accurate data collection would contribute to Nigeria’s ability to track contracep-
tive use. During the monitoring visits, many PPMVs cited police harassment for why they did not keep up-to-
date records. Future interventions should work with regulatory and law enforcement bodies to ensure they are 
aware of  PPMVs’ role in the delivery of  injectable contraceptive services. Additional research is also needed on 
how to effectively motivate PPMVs to keep records.
There are many strengths to this study: 
1. It was a systematic study that demonstrated PPMVs across all six geopolitical zones can provide both 
intramuscular and sub-cutaneous forms of  the injectable contraceptive
2. Stakeholders were an integral part of  the study’s implementation which underpins research utilization. 
For example, the Bauchi commissioner of  health has expressed her dedication in scaling-up PPMV pro-
vision of  injectable services in her state.
Study implications and recommendations
Under the proper legal and regulatory framework, PPMVs have the potential to improve access to FP ser-
vices. Results from Bauchi, Cross River, Ebonyi, Kaduna, Nasarawa and Oyo suggest that PPMVs can provide 
injectable contraceptives safely with proper training and support. Results from the PPMV and client data con-
firm that there is a demand for injectable contraceptive services from PPMVs. More importantly, clients who 
received services from PPMVs reported high quality of  care and were satisfied with the services received. 
After the training, PPMVs, regardless of  their previous experience working in the formal health sector, demon-
strated (a) the steps for safe administration, (b) that they could adhere to needle safety best practices, and (c) 
that they could gain the key knowledge to provide injectable services. While knowledge was lower for some 
indicators, specifically some of  the side effects and exclusionary health conditions, most PPMVs reported using 
job aids to counsel and screen clients. 
With input from various stakeholders, the training curriculum was revised based on learnings from Nasarawa 
and Oyo and is now ready to be used in all states for scale-up if  PPMVs are authorized to provide injectable 
contraceptive services. Based on these findings, the Evidence Project makes the following recommendations if  
policy change allows for PPMV provision of  injectable contraceptive services:
• All PPMVs should be trained using existing and validated materials. Most PPMVs in the addi-
tional four states strongly agreed that the curriculum used in this study improved their knowledge and 
skills to provide FP counseling and injectable contraceptive services.
• PPMVs should be provided job aids to for FP counseling and to counsel and screen injectable 
contraceptive clients. 
• Linkages between the PPMVs and the public sector are needed to ensure proper referrals for 
any contraceptive method and disposal of  sharps.
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• PPMVs require monitoring support by the state and local governments. Additional support 
would be needed to ensure PPMVs do not experience harassment from law officials. This potential 
for harassment can prohibit PPMVs from keeping up-to-date records of  FP counseling, and sale and 
administration of  injectable contraceptive services. 
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